October 2017

The authors discuss the current standard of care and review the new data for immunotherapy in advanced merkel cell carcinoma (MCC).

Amultihistology basket study proved the targetability of the <em>AKT1 E17K</em> mutation in human cancers by treating patients with various types of cancer harboring an <em>AKT1 E17K </em>mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the <em>Journal of Clinical Oncology</em>.

Mark E. Robson, MD, discusses the progress that has been seen in breast cancer care with the use of PARP inhibitors.

In an interview, Jonathan E. Rosenberg, MD, discusses the guidelines and their significance for the treatment of patients with muscle-invasive bladder cancer.

A multidisciplinary set of guidelines for the treatment of patients with nonmetastatic muscle-invasive bladder cancer has been created as a result of a new collaboration between the American Urological Association and several other prominent urological groups.&nbsp;The new guidelines provide a risk-stratified clinical framework to better diagnose, treat, and manage the disease.&nbsp;

An overall response rate of 16% was demonstrated in patients with FGF 19 immunohistochemistry-positive hepatocellular carcinoma treated with BLU-554, which was higher than the response rates of 10% or less that are seen with the currently approved HCC treatments.

Researchers are seeking prognostic biomarkers for response to treatment with adjuvant sorafenib (Nexavar) in patients with hepatocellular carcinoma, according to a presentation during the&nbsp;2017 International Liver Cancer Association Annual Conference in Seoul, South Korea.